12,000 Shares in Certara, Inc. (NASDAQ:CERT) Bought by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC purchased a new stake in shares of Certara, Inc. (NASDAQ:CERT) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 12,000 shares of the company’s stock, valued at approximately $128,000.

Other hedge funds also recently added to or reduced their stakes in the company. Wasatch Advisors LP lifted its stake in Certara by 22.4% during the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after acquiring an additional 1,651,076 shares during the period. Geneva Capital Management LLC boosted its position in Certara by 0.7% in the third quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock worth $64,525,000 after purchasing an additional 37,392 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Certara by 40.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after purchasing an additional 1,128,006 shares during the period. State Street Corp increased its position in shares of Certara by 3.4% during the 3rd quarter. State Street Corp now owns 3,679,699 shares of the company’s stock valued at $43,089,000 after purchasing an additional 122,411 shares during the last quarter. Finally, Brown Brothers Harriman & Co. purchased a new stake in shares of Certara during the 3rd quarter valued at about $27,292,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Trading Down 1.0 %

Shares of NASDAQ CERT opened at $13.86 on Wednesday. Certara, Inc. has a 1-year low of $9.41 and a 1-year high of $19.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The business’s 50 day moving average is $11.90 and its two-hundred day moving average is $11.70. The stock has a market capitalization of $2.23 billion, a P/E ratio of -69.30, a PEG ratio of 9.33 and a beta of 1.57.

Analyst Upgrades and Downgrades

CERT has been the subject of several recent research reports. Barclays cut their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Robert W. Baird reduced their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $15.92.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.